Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Nov;75(11):1547–1551. doi: 10.1136/jnnp.2003.025551

Does reducing spasticity translate into functional benefit? An exploratory meta-analysis

H Francis 1, D Wade 1, L Turner-Stokes 1, R Kingswell 1, C Dott 1, E Coxon 1
PMCID: PMC1738826  PMID: 15489384

Abstract

Background: Spasticity and loss of function in an affected arm are common after stroke. Although botulinum toxin is used to reduce spasticity, its functional benefits are less easily demonstrated. This paper reports an exploratory meta-analysis to investigate the relationship between reduced arm spasticity and improved arm function.

Method: Individual data from stroke patients in two randomised controlled trials of intra-muscular botulinum toxin were pooled. The Modified Ashworth Scale (elbow, wrist, fingers) was used to calculate a "Composite Spasticity Index". Data from the arm section of the Barthel Activities of Daily Living Index (dressing, grooming, and feeding) and three subjective measures (putting arm through sleeve, cleaning palm, cutting fingernails) were summed to give a "Composite Functional Index". Change scores and the time of maximum change were also calculated.

Results: Maximum changes in both composite measures occurred concurrently in 47 patients. In 26 patients the improvement in spasticity preceded the improvement in function with 18 showing the reverse. There was a definite relationship between the maximum change in spasticity and the maximum change in arm function, independent of treatment (ρ = –0.2822, p = 0.0008, n = 137). There was a clear relationship between the changes in spasticity and in arm function in patients treated with botulinum toxin (Dysport) at 500 or 1000 units (ρ = –0.5679, p = 0.0090, n = 22; ρ = –0.4430, p = 0.0018, n = 47), but not in those treated with placebo or 1500 units.

Conclusions: Using a targeted meta-analytic approach, it is possible to demonstrate that reducing spasticity in the arm is associated with a significant improvement in arm function.

Full Text

The Full Text of this article is available as a PDF (175.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ada L., Canning C., Dwyer T. Effect of muscle length on strength and dexterity after stroke. Clin Rehabil. 2000 Feb;14(1):55–61. doi: 10.1191/026921500671430626. [DOI] [PubMed] [Google Scholar]
  2. Bakheit A. M., Pittock S., Moore A. P., Wurker M., Otto S., Erbguth F., Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001 Nov;8(6):559–565. doi: 10.1046/j.1468-1331.2001.00277.x. [DOI] [PubMed] [Google Scholar]
  3. Bakheit A. M., Thilmann A. F., Ward A. B., Poewe W., Wissel J., Muller J., Benecke R., Collin C., Muller F., Ward C. D. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000 Oct;31(10):2402–2406. doi: 10.1161/01.str.31.10.2402. [DOI] [PubMed] [Google Scholar]
  4. Bhakta B. B., Cozens J. A., Bamford J. M., Chamberlain M. A. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):30–35. doi: 10.1136/jnnp.61.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhakta B. B., Cozens J. A., Chamberlain M. A., Bamford J. M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217–221. doi: 10.1136/jnnp.69.2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bohannon R. W., Smith M. B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206–207. doi: 10.1093/ptj/67.2.206. [DOI] [PubMed] [Google Scholar]
  7. Brashear Allison, Gordon Mark F., Elovic Elie, Kassicieh V. Daniel, Marciniak Christina, Do Mai, Lee Chia-Ho, Jenkins Stephen, Turkel Catherine, Botox Post-Stroke Spasticity Study Group Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395–400. doi: 10.1056/NEJMoa011892. [DOI] [PubMed] [Google Scholar]
  8. Brin M. F. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997;6:S208–S220. doi: 10.1002/(sici)1097-4598(1997)6+<208::aid-mus15>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  9. Burbaud P., Wiart L., Dubos J. L., Gaujard E., Debelleix X., Joseph P. A., Mazaux J. M., Bioulac B., Barat M., Lagueny A. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):265–269. doi: 10.1136/jnnp.61.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Canning C. G., Ada L., O'Dwyer N. Slowness to develop force contributes to weakness after stroke. Arch Phys Med Rehabil. 1999 Jan;80(1):66–70. doi: 10.1016/s0003-9993(99)90309-x. [DOI] [PubMed] [Google Scholar]
  11. Collin C., Wade D. T., Davies S., Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10(2):61–63. doi: 10.3109/09638288809164103. [DOI] [PubMed] [Google Scholar]
  12. Lagalla G., Danni M., Reiter F., Ceravolo M. G., Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil. 2000 Jul-Aug;79(4):377–394. doi: 10.1097/00002060-200007000-00010. [DOI] [PubMed] [Google Scholar]
  13. Ottenbacher K. J., Cusick A. Goal attainment scaling as a method of clinical service evaluation. Am J Occup Ther. 1990 Jun;44(6):519–525. doi: 10.5014/ajot.44.6.519. [DOI] [PubMed] [Google Scholar]
  14. Richardson D., Sheean G., Werring D., Desai M., Edwards S., Greenwood R., Thompson A. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):499–506. doi: 10.1136/jnnp.69.4.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rodriquez A. A., McGinn M., Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil. 2000 Jan-Feb;79(1):44–47. doi: 10.1097/00002060-200001000-00010. [DOI] [PubMed] [Google Scholar]
  16. Sheean G. L. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol. 2001 Dec;14(6):771–776. doi: 10.1097/00019052-200112000-00015. [DOI] [PubMed] [Google Scholar]
  17. Simpson D. M., Alexander D. N., O'Brien C. F., Tagliati M., Aswad A. S., Leon J. M., Gibson J., Mordaunt J. M., Monaghan E. P. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996 May;46(5):1306–1310. doi: 10.1212/wnl.46.5.1306. [DOI] [PubMed] [Google Scholar]
  18. Smith S. J., Ellis E., White S., Moore A. P. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000 Feb;14(1):5–13. doi: 10.1191/026921500666642221. [DOI] [PubMed] [Google Scholar]
  19. Snow B. J., Tsui J. K., Bhatt M. H., Varelas M., Hashimoto S. A., Calne D. B. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990 Oct;28(4):512–515. doi: 10.1002/ana.410280407. [DOI] [PubMed] [Google Scholar]
  20. Yablon S. A., Agana B. T., Ivanhoe C. B., Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996 Oct;47(4):939–944. doi: 10.1212/wnl.47.4.939. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES